Cipla Ltd is quoting at Rs 1286.4, down 1.05% on the day as on 13:19 IST on the NSE. The stock tumbled 14.73% in last one year as compared to a 3.15% rally in NIFTY and a 7.68% spurt in the Nifty ...
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the ...
While Nifty Pharma giants struggle with regulatory headwinds and pricing pressures, two outliers are quietly catching the ...
Cipla USA has recalled unexpired batches of Lanreotide Injection, resulting in a temporary market shortage. The recall ...
Cipla USA, a subsidiary of the Indian drugmaker, is recalling over 400 cartons of generic anti-cancer drug Nilotinib due to a manufacturing issue. The recall is classified as Class III by the USFDA, ...
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement ...
Cipla USA has recalled over 400 cartons of Nilotinib Capsules used to treat blood cancers after they failed to meet specifications, according to the U.S. Food and Drug Administration, which classified ...
More than 400 cartons of Nilotinib capsules were voluntarily recalled by Cipla USA after failing manufacturing specifications ...
Top 30 pharma companies post 12% revenue growth in first nine months, net profit up only by 2.8%: Sanjay Pingle, Mumbai Friday, March 13, 2026, 08:00 Hrs [IST] The aggregate finan ...
Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing issue where the capsules failed to meet specifications. This is a voluntary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results